REMGRO LIMITED - Summary of Mediclinic Holdings Limited results for the year ended 31 March 2026
What this filing means
Remgro's voluntary disclosure of Mediclinic's FY26 results reveals a $733m net loss driven by massive Swiss impairments, overshadowing a 45% increase in adjusted operating earnings.
Remgro released the financial results for its hospital business, Mediclinic. While the hospitals made more money from daily operations, the company had to wipe over $1.2 billion off the official value of its Swiss assets, leading to a large overall loss on paper.
Bull case
- Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.
- Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.
Bear case
- Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.
- The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.
AI-generated summary by SENS-AI, based on the original JSE SENS filing.
SENS-AI conclusion
Remgro voluntarily published Mediclinic's FY26 financial summary, disclosing a $733m net loss driven by $1.244bn in Swiss and restructuring-related impairments, alongside a 45% rise in adjusted earnings to $345m. The divergence highlights that while underlying operational cash conversion and margins improved, significant value destruction occurred in the Swiss division ahead of the planned MCSA and Hirslanden ownership split. This update provides Mediclinic's unreviewed standalone figures only and does not establish Remgro's consolidated group financials or dividend expectations. Investor Takeaway: The strong operational performance of the underlying assets is heavily overshadowed by the $1.244bn impairment hit, making it a mixed update that leaves the broader restructuring thesis intact but rebased.
The unreviewed Mediclinic figures highlight strong underlying cash generation but reveal massive write-downs in the Swiss division ahead of the planned split. No immediate portfolio action required for Remgro holders.
Decision framework
Current stance: Filing Negative
Key drivers
- Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.
- Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.
Key risks
- Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.
- The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.
What would change the view
- Management provides credible upward guidance with measurable support.
- Margin/cash-flow quality improves in the next reporting cycle.
- Risk factors in this filing are explicitly resolved by subsequent disclosures.
Evidence from the filing
Adjusted EBITDA grew by 14% to $842m, with the EBITDA margin expanding to 15.7% supported by revenue growth and cost efficiencies.
“Adjusted EBITDA increased by 14% to $842m (FY25: $737m) and 8% in constant currency terms. The Group's adjusted EBITDA margin was 15.7% (FY25: 15.3%), supported by a combination of revenue growth and cost efficiencies.”
Balance sheet discipline improved, with the leverage ratio reducing to 2.7x from 3.1x and cash conversion strengthening to 106%.
“Leverage ratio reduced to 2.7x (FY25: 3.1x)”
Headline growth was significantly flattered by currency translation, as adjusted revenue growth of 11% drops to only 5% in constant currency terms.
“Adjusted revenue increased by 11% to $5 356m (FY25: $4 818m), up 5% in constant currency terms. ... Adjusted EBITDA increased by 14% to $842m (FY25: $737m) and 8% in constant currency terms.”
The restructuring of MCSA and Hirslanden into disposal groups held for sale compromises historical comparability and introduces complexity in assessing ongoing value.
“As a result, the MCSA and Hirslanden divisions have been classified as disposal groups held for sale and presented as discontinued operations in terms of IFRS 5.”
More on Remgro Limited
Related filings
More from REM
- REMGRO LIMITED - Notice of an acquisition of a beneficial interest in Remgro Limited securities
- REMGRO LIMITED - Notice of an acquisition of a beneficial interest in Remgro Limited securities
- REMGRO LIMITED - Restructuring of interests in Mediclinic Holdings implementation of transaction
- REMGRO LIMITED - Completion of disposal of shares held in FirstRand Limited
- REMGRO LIMITED - Dealings in securities by an executive director
Other Results
- SUISUN INTERNATIONAL LIMITED - Unaudited Interim Group Financial Results, Interim Ordinary Cash Dividend Declaration for the six months ended 30 June 2026 and Changes to Risk Committee Responsibilities
- AVIAVI LIMITED - RESULTS FOR THE YEAR ENDED 30 JUNE 2026, AND FINAL AND SPECIAL DIVIDEND
- BELBELL EQUIPMENT LIMITED - Unaudited Condensed Consolidated Interim Financial Statements for the six months ended 30 June 2026 and Dividend Declaration
- ARIAFRICAN RAINBOW MINERALS LIMITED - Condensed Reviewed Results for the financial year ended 30 June 2026 and Final Cash Dividend Declaration
- AIRPORTS COMPANY SOUTH AFRICA SOC LIMITED - Invitation to the Release of the Annual Financial Results